Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Gross Profit (2020 - 2025)

Maravai Lifesciences Holdings (MRVI) has 6 years of Gross Profit data on record, last reported at $12.8 million in Q4 2025.

  • For Q4 2025, Gross Profit fell 33.77% year-over-year to $12.8 million; the TTM value through Dec 2025 reached $34.0 million, down 68.62%, while the annual FY2025 figure was $34.0 million, 68.62% down from the prior year.
  • Gross Profit reached $12.8 million in Q4 2025 per MRVI's latest filing, up from $5.7 million in the prior quarter.
  • Across five years, Gross Profit topped out at $205.2 million in Q2 2022 and bottomed at $5.7 million in Q3 2025.
  • Average Gross Profit over 5 years is $82.8 million, with a median of $35.6 million recorded in 2023.
  • Peak YoY movement for Gross Profit: surged 601.19% in 2021, then tumbled 87.51% in 2023.
  • A 5-year view of Gross Profit shows it stood at $187.8 million in 2021, then decreased by 19.36% to $151.5 million in 2022, then crashed by 74.23% to $39.0 million in 2023, then plummeted by 50.32% to $19.4 million in 2024, then plummeted by 33.77% to $12.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Gross Profit were $12.8 million in Q4 2025, $5.7 million in Q3 2025, and $7.8 million in Q2 2025.